Darolutamide Plus ADT in Metastatic Hormone-Sensitive Prostate Cancer
Clinical Summary:
- Design/Context: In this open-label study, researchers compared darolutamide plus ADT with a propensity score–matched ADT control arm from the CHAARTED trial in metastatic hormone-sensitive prostate cancer.
- Key Outcomes: Darolutamide plus ADT significantly improved progression-free survival, overall survival, radiographic progression-free survival, and time to metastatic castration-resistant prostate cancer.
- Clinical Relevance: These findings reinforce the efficacy and safety of darolutamide plus ADT in mHSPC and support its use as a standard treatment option in this setting.
Rana McKay, MD, University of California, San Diego, California, discusses results from the ARASEC trial evaluating darolutamide plus androgen deprivation therapy (ADT) among patients with metastatic hormone-sensitive prostate cancer.
Results demonstrated that this combination significantly improves survival and disease control in metastatic hormone-sensitive prostate cancer.
Dr McKay presented these results at the 2026 American Urological Association (AUA) Annual Meeting in Washington, District of Columbia.
Source:
McKay RR, Ross AE, Preston MA, et al. Darolutamide plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (MHSPC): ARASEC – US prospective, open-label phase 2 study with an external control arm. J Urol. Published online: May 1, 2026. doi:10.1097/01.JU.0001192572.07890.f8.08
